TRCT
LIMN

Tower Research Capital (TRC)’s Liminatus Pharma LIMN Stock Holding History

Tower Research Capital (TRC)’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$783 Sell
7,093
-474
-6% -$82 ﹤0.01% 4947
2026
Q1 		$1.3K Sell
7,567
-1,336
-15% -$712 ﹤0.01% 4687
2025
Q4 		$5.43K Buy
8,903
+7,055
+382% +$7.83K ﹤0.01% 4125
2025
Q3 		$3.09K Buy
1,848
+1,340
+264% +$5.78K ﹤0.01% 4547
2025
Q2 		$5.66K Buy
+508
New +$5.7K ﹤0.01% 4160

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tower Research Capital (TRC)'s LIMN Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Liminatus Pharma (LIMN) stake by 6.3% in Q2 2026, selling an estimated $82 and leaving 7,093 shares worth $783. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

Tower Research Capital (TRC) first reported a position in LIMN in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.66K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Tower Research Capital (TRC) held 7,093 shares of Liminatus Pharma worth $783 as of Q2 2026.
  • Tower Research Capital (TRC) sold 474 Liminatus Pharma shares in Q2 2026, an estimated $82.
  • Liminatus Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4947 holding.
  • Tower Research Capital (TRC) first reported a position in Liminatus Pharma in Q2 2025 and has held it in 5 quarters since.
  • Tower Research Capital (TRC)'s Liminatus Pharma position peaked at $5.66K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.